Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene — p53 — is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.

More: continued here

This entry was posted on Thursday, May 15th, 2008 at 9:05 pm and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.